# Multi-omics Mendelian randomisation using expression, splicing and protein quantitative trait loci: identification of novel drug targets for gliomagenesis

## Authors and Affiliations

Zak A Thornton, [1 2 3]* Lily J Andrews, [1 2 3] Huiling Zhao, [1]Jie Zheng, [1 4 5] Lavinia Paternoster, [1 2 6] Jamie W Robinson, [1]† and Kathreena M Kurian [1 2 3 7]*†

[1] MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, BS8 1QU, United Kingdom

[2] Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

[3] Cancer Research Integrative Cancer Epidemiology Programme, University of Bristol, Bristol, UK

[4] Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[5] Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[6] NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol

[7] Brain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK

† Co-senior author

## Contact Information

* Corresponding authors: Mr Zak Thornton – zak.thornton@bristol.ac.uk; Professor Kathreena Kurian – kathreena.kurian@bristol.ac.uk

# Abstract

**Background:** Genetic variants associated with molecular traits that are also associated with liability to glioma can provide causal evidence for the prioritisation of these traits as candidate drug targets.

**Methods:** We performed two-sample Mendelian randomisation and genetic colocalisation of a large panel of molecular traits on glioma. Molecular data were taken from studies of expression quantitative trait loci (QTL) [11,985 genes]; splicing QTL [13,285 genes] and protein QTL [7,376 proteins] derived from 15 brain tissues. Glioma summary-level data was extracted from a genome-wide association meta-analysis of 12,496 cases and 18,190 controls.

**Results:** Our MR analysis showed evidence for a causal effect of 85 molecular traits on glioma – 37 were robust according to colocalisation and Steiger filtering. We found causal evidence for 10 genes previously associated with glioma risk. We identified one novel genetic locus with strong causal evidence in the gene expression analysis: *HBEGF* (5q31.3) in all glioma [OR 1.36 (95%CI 1.19 to 1.55); P = $4.41 \times 10^{-6}$]. We also identified three novel genetic loci with strong causal evidence in the splicing variation analysis: *CEP192* (18p11.21) in glioblastoma [OR 4.40 (95%CI 2.28 to 8.48); P = $9.78 \times 10^{-4}$]; *FAIM* (3q22.3) in all glioma [OR 2.72 to 3.43; P = $1.03 \times 10^{-5}$ to $1.09 \times 10^{-5}$] and *SLC8A1* (2p22.1) in all glioma [OR 0.37 (95%CI 0.24 to 0.56; P = $5.72 \times 10^{-6}$].

**Conclusions:** We provide robust causal evidence for genes previously associated with glioma risk in genome-wide association studies, as well as four novel genes.


**Keywords:** glioma, Mendelian randomisation, quantitative trait loci, molecular traits

# Introduction

Glioma is the most common (~80%) primary malignant brain and central nervous system (CNS) tumour group, with age-standardised incidence rates ranging from 4.67 to 5.73 per 100,000. [1,2] Malignant brain tumours are responsible for the greatest years of potential life lost of all cancers (~20 years), with a comparatively shorter 5-year relative survival rate (34.9%) compared to other malignancies. [3,4]

In the 2016 World Health Organisation (WHO) guidelines for diagnosis of brain tumours, histological markers formed a sufficient basis to classify CNS tumours; however, this was expanded in the latest 2021 edition, which suggests molecular profiling as a means of stratifying tumour types. [5,6] The reason for this change is to emphasise the shift in how glioma, and brain tumours in general, are now classified in the clinic. One key example is the use of *MGMT* methylation as a tool to stratify patients in clinical trials. [7,8] However, the molecular landscape of glioma remains complex and heterogeneous, highlighting an area of unmet research need to improve diagnosis, patient stratification and, hopefully, treatment.

One approach to elucidating novel molecular markers comes from the field of genetic epidemiology in the way of genome-wide association studies (GWAS) and transcriptome-wide association studies (TWAS), two study designs which leverage large-scale human genotyping of genetic variation to determine which genes are associated with a phenotype of interest. To date, previous studies have identified 27 genetic loci associated with glioma risk, implicating a total of approximately 50 genes; however, further analysis is required to determine both which genes these genetic variants map to, and whether such variation is causally implicated in gliomagenesis, or simply an observational association. [9-14]

Furthermore, genotyping of large cohorts has been performed to link disease-associated genetic variants to gene regulatory mechanisms to improve understanding of disease aetiology. [15] Such genetic variants associated with these molecular traits are known as quantitative trait loci (QTL), and

68 examples of these include measuring relative gene expression levels (eQTLs), splicing variation
69 (sQTLs) and protein abundance (pQTLs). Integrating multi-dimensional omics data can further our
70 understanding of the aetiology of complex traits by providing functional and mechanistic insight into
71 these layered molecular relationships. [16-18]

72 Mendelian randomisation (MR) is an established statistical method which utilises genetic predictors
73 of an exposure to assess the causal relationship between this exposure and an outcome. [19] The main
74 advantage MR has over traditional observational epidemiological methods is that MR can determine
75 causality between an exposure and an outcome as it is less liable to common epidemiological biases,
76 such as confounding and reverse causality. When combined with other sensitivity analyses such as
77 genetic colocalisation, MR can provide strong evidence of an unbiased causal relationship between
78 genes and traits of interest. [20]

79 In this study, we leveraged multi-dimensional QTL data derived in bulk brain tissues in a combined
80 MR-colocalisation framework, with the aim to identify causal evidence for aetiologically important
81 genes for gliomagenesis.

# Methods

A diagram of the workflow described in this section can be found in Figure 1.

## Study Datasets

We used QTL summary statistics from genome-wide association studies (GWAS) of gene expression, protein abundance and alternative splicing levels in various brain tissues described below. Overviews of these datasets are given in Supplementary Table S1.

Gene expression data were taken from MetaBrain, a meta-analysis of 14 eQTL datasets derived from 3,659 samples from 2,683 individuals of European ancestry in five CNS tissues: the basal ganglia (n=208), cerebellum (n=492), cortex (n=2,683), hippocampus (n=168), and spinal cord (n=108) (Supplementary Table S1). [21]

The sQTL data were taken from GTEx Portal (v8 release). We used sGenes provided by GTEx, generated using their QC protocol, from a primarily European-American (85.3%) population. sQTL were extracted from 13 regions of the CNS: amygdala (n=129), anterior cingulate cortex (BA24) (n=147), caudate (n=194), cerebellar hemisphere (n=175), cerebellum (n=209), cortex (n=205), frontal cortex (BA9) (n=175), hippocampus (n=165), hypothalamus (n=170), nucleus accumbens (n=202), putamen (n=170), spinal cord (n=126), and substantia nigra (n=114) (Supplementary Table S1). [22]

Finally, we included pQTL data retrieved from BrainQTL, derived from European ancestry individuals in the religious orders study and memory and ageing projects. [23,24] pQTL were extracted from the dorsolateral pre-frontal cortex of 330 individuals (Supplementary Table S1). [25]

Glioma summary-level data were derived from a meta-analysis of eight constituent glioma GWAS consisted of 6,191 glioblastoma (GB) cases, 5,819 non-GB cases, 12,496 combined cases and 18,190 controls. [9] We therefore used three outcomes throughout our analyses: the GB-only case load, the non-GB-only case load, and the combined case load (defined as 'all glioma'). Although glioma is

highly heterogeneous, we did this to increase our statistical power by using larger sample sizes. The non-GB cases analysed in this meta-analysis were not explicitly classified but consists mainly of astrocytoma and oligodendroglioma diagnosed patients (Supplementary Table S1).

This study uses previously published summary-level data and thus contains no patient identifiable data. Ethical approval and informed consent from each participant were given and can be found where the dataset was initially described. All procedures performed in studies involving human participants were done in accordance with the ethical standards of the institutional or national research committee and with 1964 Helsinki declaration.

## Instrument Selection

We identified *cis*-acting (within 1Mb of the gene coding region) QTLs which met genome-wide significance ($P < 5x10^{-8}$). *Trans*-acting QTLs were excluded from the analysis because of the increased likelihood of horizontal pleiotropy, due to their distant location from the gene whose variation they alter. Instruments were selected to be in linkage disequilibrium ($R^2 < 0.001$) to ensure independence.

## Two Sample Mendelian Randomisation

We used a two-sample MR framework to estimate the causal effect of genetically proxied gene expression, protein abundance and alternative splicing on genetic liability to glioma risk. MR estimates were generated using the Wald ratio method for instruments consisting of single SNPs and inverse variance weighted (IVW) method for instruments comprising of multiple SNPs. [26] MR estimates were transformed and presented throughout as odds ratios (OR) and were scaled to reflect one standard deviation increase in the respective molecular trait. Following MR analysis, the results had to meet a Bonferroni-corrected P value threshold (0.05/number of tests performed) to adjust for multiple testing.

MR has three assumptions which must hold to produce an unbiased estimate. Firstly, the genetic instrument must associate with the exposure ('relevance'). We tested this by generating the F-

statistic for each instrument, where an F-statistic > 10 is evidence against weak instrument bias, and filtering out instruments which did not surpass this threshold. [27,28] The second assumption is that the genetic instrument does not share a common cause with the outcome ('independence'). We tested this assumption partly by using genetic colocalisation, which determines whether the molecular trait and glioma share the same causal variant, a necessary (though not sufficient) condition for causality. Using colocalisation in this way has been posited to at least eliminate some unreliable associations when standard follow up sensitivity analyses to evaluate the presence of horizontal pleiotropy (such as MR-Egger) are unavailable. [27,29] The final assumption is that the genetic instrument affects the outcome only through the effect of the exposure of interest ('exclusion restriction'). This assumption, also known as horizontal pleiotropy, is difficult to assess with single SNP instruments, as is common for 'omic' variables. This was tested by investigating whether there was causal evidence linking the molecular trait of interest with putative risk factors for glioma. The presence of an association between the molecular trait and glioma risk factors may then be evidence of potential horizontal pleiotropy (Figure 2). [27]

For brevity, we refer to our MR results as causal genes (or causal proteins); however, we recognise that further studies and evidence will be required to validate our results.

## Colocalisation

We tested for colocalisation between the loci of each molecular trait and glioma subtype which had an MR result that passed the Bonferroni-corrected P value threshold. We extracted *cis*-regions consisting of all SNPs within a 1Mb window around the gene coding regions. [20] Colocalisation requires the *cis*-region of the molecular trait to be richly genotyped. If there were not enough SNPs to perform colocalisation, we used LDCheck to measure the pairwise LD between the QTL and *cis*-SNPs in the glioma data at a more lenient threshold ($P < 5 \times 10^{-6}$). If the SNPs were in high LD ($R^2 > 0.8$), then we took this as proxy, albeit weak, evidence for colocalisation. This method has been described and used previously when full genome-wide statistics were not available. [30]

## Steiger Filtering

For causal effects which had strong evidence of colocalisation, we applied Steiger filtering to test for the presence of reverse causation, where the instrument explains more of the variance in the outcome than the exposure. [29] Results of Steiger filtering are presented as a one of three categorical variables; "pass" if Steiger $P < 0.05$ and the instrument explains more of the variance in the outcome than the exposure, "fail" if Steiger $P < 0.05$ and the instrument explains more of the variance in the exposure than the outcome, and "uncertain" if $P \geq 0.05$.

## Evidence thresholds for multi-omic analyses

Our main results comprised of those which passed the Bonferroni correction P value, had strong colocalisation evidence ($H_4 \geq 80\%$) and passed Steiger filtering sensitivity analysis, as they have the most robust evidence. Since Steiger filtering is sensitive to sample sizes, the analysis may be liable to false negatives if one dataset is better powered than the other; therefore, given the relatively small samples in the QTL datasets, we included results which had "uncertain" evidence but with the caveat that these results may be less robust.

## Overlap in signals between molecular traits

To determine whether there was any potential overlap in signals between molecular traits, we looked at all MR results for our molecular traits with robust evidence in all tissues, regardless of P value. We then filtered these results using a more lenient Bonferroni correction P value (similarly, by using 0.05/number of tests performed) to determine whether any were potentially overlapping signals which failed to pass due to insufficient statistical power.

## Specificity Analysis

To annotate the potential causal pathway between the molecular trait and glioma, we used two different approaches: exploring PheWAS data, and risk factors with pre-existing evidence in the literature. To perform a broad search for potential causal pathways, we used the IEU OpenGWAS

project PheWAS tool and PhenoScanner V2 to search for phenotypes which were strongly associated ($P < 5 \times 10^{-8}$) with lead SNPs used to instrument the robust causal effects. [31-33] We then performed a specificity analysis to determine whether the robust causal effects were being caused by non-specific effects or driven through a putative risk factor for glioma. We investigated risk factors with genetic liability to allergies, asthma, altered low-density lipoprotein cholesterol (LDLc) levels and alcohol consumption. These risk factors were selected based on potential evidence linking that risk factor to glioma in the literature, if there was data available for that risk factor in the IEU OpenGWAS project database, and whether those data were available for use in an MR analysis. [34]

## Differential expression in molecular traits

We explored whether there was differential expression in the genes for which there was robust evidence that expression had a causal effect on at least one glioma subtype, between subtypes of glioma and control patients using the GlioVis resource. [35]

We investigated the differences in the expression of splicing variants in tissue types in the genes for which there was evidence that gene-splicing had a causal effect on at least one glioma subtype, using the GTEx portal. [22]

## Annotation of ‘druggability’

We annotated robust results which passed sensitivity analyses with evidence of 'druggability’, i.e. how likely a gene and its gene product are to be a valid drug target, to build evidence for the prioritisation of genes and proteins as candidate targets. We used the Open Targets platform, a large-scale database that uses genetic and genomic data for systematic drug target identification and prioritisation, to search for gene ontology terms, pathways, and gene interactions. [36,37] We also used Drug Gene Interaction Database (DGIdb) to search for drug-gene interactions and genome ‘druggability’. [38]

## Software

We used the TwoSampleMR R package to implement the MR analyses and Steiger filtering. [39-41] We performed genetic colocalisation using Pair Wise Conditional Analysis and Colocalisation (PWCoCo), a method which combines Conditional and Joint Analysis (GCTA-COJO) and colocalisation (Coloc R package) to ensure the single causal variant assumption of colocalisation holds. [20,42,43]

# Results

## Estimating the causal effects of gene expression on glioma risk

Of the 10,488 genes for which expression could be instrumented, 10,006 (95.4%) had the relevant SNPs available in the glioma GWAS and therefore MR could be performed. We found 29 genes with evidence for a causal effect ($P < 5.00 \times 10^{-6}$) on all glioma, GB, or non-GB in at least one of the tissues tested, resulting in 80 causal effects in total; 40 causal effects in cortex, 30 in cerebellum, 6 in basal ganglia, 3 in hippocampus and 1 in spinal cord (Supplementary Figure S1). In the follow-up sensitivity analyses of the unique 80 expression causal effects, we found that 30 (38%) had strong evidence of colocalisation ($H_4 > 80\%$), 11 (14%) had moderate evidence of colocalisation ($80\% > H_4 > 50\%$) and 39 (49%) had weak evidence of colocalisation ($H_4 < 50\%$). The 30 causal effects (in 10 genes) with strong evidence for colocalisation were then tested for the potential of reverse causality using Steiger filtering; 29 causal effects passed this test, whilst one result was uncertain according to Steiger P-value ($P > 0.05$, Table 1).

Three genes (*GALNT6, HEATR3, PICK1*) with robust evidence of a causal effect were identified in multiple tissues, with different lead SNPs, but all SNPs were in high LD ($R^2 > 0.7$). [30] Two genes (*JAK1* and *PICK1*) with robust evidence had a causal effect in only one subtype (non-GB and GB, respectively) whereas all other genes (CDKN2B, *EGFR, GALNT6, HBEGF, HEATR3, MDM4, RAVER2* and *TERT*) had a causal effect on all glioma, or more than one outcome tested (Table 1).

225 In summary, we found 10 genes for which there was robust evidence that expression had a causal
226 effect on at least one glioma subtype in at least one brain region (30 causal effects in total, Figure 3).
227 Three genes (*CDKN2B, RAVER2, TERT*) had strong causal effects (OR <0.5 or >2). For six genes,
228 increased expression was causally related to increased odds of glioma. All results for all eQTL
229 sensitivity analyses are described in Supplementary Table S1.

## 230 Estimating the causal effects of alternative splicing on glioma risk

231 Of the 6,200 genes for which alternative splicing could be instrumented, 4,496 (72.5%) had the
232 relevant SNPs available in the glioma GWAS are therefore MR could be performed. We found 10
233 genes with evidence for a causal effect ($P < 1.11 \times 10^{-5}$) on glioma, GB or non-GB in at least one of
234 the thirteen tissues tested, resulting in 71 causal effects in total; five in amygdala, four in anterior
235 cingulate cortex, seven in caudate, six in cerebellar hemisphere, nine in cerebellum, six in cortex,
236 four in frontal cortex, seven in hippocampus, seven in hypothalamus, nine in nucleus accumbens, six
237 in putamen and one in substantia nigra (Supplementary Figure S2). We applied the same sensitivity
238 analysis pipeline. We found that 47 (66%) had strong evidence of colocalisation ($H_4 > 80\%$), five (7%)
239 had moderate evidence of colocalisation ($80\% > H_4 > 50\%$) and 19 (27%) had weak evidence of
240 colocalisation ($H_4 < 50\%$). The 47 causal effects with strong evidence for colocalisation were then
241 tested for the potential of reverse causality using Steiger filtering; 24 (51%) passed this test,
242 however all of these results were uncertain according to Steiger P-value ($P > 0.05$. Table 2).

243 Three genes (*FAIM, PHLDB1, RTEL1*) had robust evidence of a causal effect on glioma risk within
244 multiple tissues, with different lead SNPs, but all were in high LD ($R^2 > 0.7$). [30] One gene (*CEP192*)
245 with robust evidence of a causal effect on GB, whereas all other genes (*FAIM, HEATR3, PHLDB1,*
246 *SLC8A1* and *RTEL1*) had a causal effect on all glioma, or more than one outcome tested (Table 2).

247 In summary, we found six genes for which there was robust evidence that splicing had a causal effect
248 on at least one glioma subtype in at least one brain region (24 causal effects in total, Figure 4). All
249 results for all sQTL sensitivity analyses are described in Supplementary Table S1.

## Estimating the causal effects of protein abundance on glioma risk

Of the 618 proteins that could be instrumented, all (100%) had the relevant SNPs available in the glioma GWAS are therefore MR could be performed. We only found one protein with evidence for a causal effect on GB in DLPFC ($P < 8.09 \times 10^{-5}$), SCFD1 (OR 0.17 (95%CI 0.07 to 0.40); $P = 6.67 \times 10^{-5}$), Supplementary Figure S3).

We applied the same sensitivity pipeline but there was not sufficient SNPs in the *cis*-region of SCFD1 to perform colocalisation. We used LDCheck (see methods) to determine weak proxy evidence of colocalisation. However, none of the SCFD1 SNPs in the glioma dataset reached our most lenient threshold of $P < 5 \times 10^{-6}$. Therefore, we could not conclude that this pQTL had sufficient causal evidence to be associated with glioma.

In summary, there were no proteins with robust causal evidence from the MR and sensitivity analyses. All results for causal pQTL sensitivity analysis are described in Supplementary Table S1.

## Novel genes

From our multi-omic analysis, we found robust evidence for four genes that not been implicated with glioma risk in previous genetic studies: *CEP192* (18p11.21), *FAIM* (3q22.3), *HBEGF* (5q13.3) and *SLC8A1* (2p22.1).

We found that increased *HBEGF* expression in the cortex is causal for all glioma (OR 1.36 (95%CI 1.19 to 1.55); $P = 4.41 \times 10^{-6}$). We found there was also increased risk of glioma in the GB and non-GB subtypes in the cortex, but they did not meet our Bonferroni-corrected P value threshold ($P = 5.53 \times 10^{-6}$ and $2.01 \times 10^{-2}$, respectively) (Table 1, Figure 5).

We found that *FAIM* isoforms in four tissues were causal for all glioma (OR 2.72 to 3.43; $P = 1.03 \times 10^{-5}$ to $1.09 \times 10^{-5}$). There was also an increased risk of glioma in the GB and non-GB subtypes in these tissues, but they failed to meet our Bonferroni-corrected P value threshold ($P = 4.36 \times 10^{-5}$ to $9.64 \times 10^{-3}$). We found that *CEP192* splicing in the cerebellar hemisphere is causal for GB (OR 4.40

(95%CI 2.28 to 8.48; P = 9.78 x $10^{-6}$). There was also an increased risk of glioma in all glioma (but not non-GB), but this failed to meet the Bonferroni-corrected P value (P = 1.74 x $10^{-3}$) (Table 2, Figure 6). We found that *SLC8A1* splicing in the substantia nigra was protective for all glioma (OR 0.37 (95%CI 0.24 to 0.56); P = 5.72 x $10^{-6}$). There was also a decreased risk of glioma in the GB and non-GB subtypes in this tissue, but they failed to meet our Bonferroni-corrected P value threshold (P = 5.67 x $10^{-4}$ and 1.81 x $10^{-4}$, respectively) (Table 2, Figure 6).

## Overlap in signals between molecular traits

We analysed all 16 robust molecular traits that we identified in our analysis in each tissue type across all three datasets, regardless of P value. We performed 104 tests, of which 82 molecular traits had passed the Bonferroni corrected P value in the primary analysis. Of the 22 other molecular traits, 12 passed the more lenient Bonferroni-corrected P value (P = 4.81 x $10^{-4}$), of which only *FAIM* in the cerebellum in all glioma (P = 6.93 x $10^{-5}$) showed potential overlap between molecular traits (gene expression and alternative splicing). Additionally, we found that the effect of *HEATR3* appears to be eQTL-specific (P = 1.95 x $10^{-10}$ to 6.74 x $10^{-12}$) despite finding a robust causal effect in the alternative splicing analysis (P = 1.29 x $10^{-10}$, Supplementary Table S2). The causal effect is likely driven through expression of the canonical gene isoform, which is incorrectly measured as an alternative splice isoform due to the way in which eQTL and sQTL are measured (see discussion).

## Specificity analysis

To annotate the potential causal pathways between the robust molecular traits and glioma, we used PheWAS data, and known glioma risk factors with pre-existing evidence. *HBEGF* is commonly linked with other cancer types so we wanted to explore this putative oncogene further. [44] Similarly, *RTEL1* is linked with telomere length which has been previously implicated in observational and MR studies to have an association with glioma risk. Additionally, the considerable number of tissues in which we found a causal effect warranted further analyses. [45-47]

We used the IEU OpenGWAS project PheWAS tool and PhenoScanner v2 to conduct a broad search for phenotypes which were strongly associated with the lead SNP(s) for *HBEGF* (rs4150197) and *RTEL1* (rs6062302, rs2297440, rs2315009, rs3208007, rs2777941) at genome-wide significance ($P < 5 \times 10^{-8}$). [31,33] We found that rs4150197 was associated with anthropometric traits such as hip circumference and weight, and various image-derived phenotypes from diffuse MRI (Supplementary Table S2). We found that rs6062302 and rs2297440 were already associated with glioblastoma ($P = 1.00 \times 10^{-13}$ and $P = 4.00 \times 10^{-46}$, respectively) and rs2297440 was associated with glioma ($P = 2.00 \times 10^{-42}$). We also found significant associations with phenotypes associated with the immune system such as dermatitis, eczema, Crohn's disease, inflammatory bowel disease and allergic rhinitis (Supplementary Table S2).

For the 16 molecular traits that had strong evidence for a causal effect on glioma, we performed a follow-up ad hoc analysis to determine whether these molecular traits also had causal evidence with putative glioma risk factors. We found that of the molecular traits with robust causal evidence, only *HBEGF* showed no evidence for non-specific effects with any of the traits we identified. The trait that was associated with the most potential glioma genes was LDLc, which was associated ($P < 0.05$) with seven genes (*CDKN2B, FAIM, GALNT6, HEATR3, PHLDB1, PICK1, RTEL1*). (Supplementary Table S2).

## Differential expression in molecular traits

We searched for differential expression of *HBEGF* using the Rembrandt and TCGA studies, found in the GlioVis tool. We found no significant differences ($P < 0.05$) between non-tumour samples and any of the glioma subtypes but did find differential expression between GB and non-GB subtypes ($P = 3.10 \times 10^{-5}$ to $1.90 \times 10^{-10}$) (Supplementary Figure S4A&B). [48]

Additionally, we searched for differences in isoform expression of *RTEL1* using the GTEx portal tool. [22] We found that isoform expression was significantly lower between wild-type (CC) and the homozygous variant (TT) in our lead SNPs ($P = 6.64 \times 10^{-18}$ to $4.23 \times 10^{-75}$). We found that the cerebellum had the highest isoform (ENST00000425905.5) expression (3.17 transcripts per million

323 (TPM)), one of the tissues in which we found our results, followed by the cerebellar hemisphere

324 (2.96 TPM) and testes (1.31 TPM). [22]

## 325 Annotation of 'druggability'

326 We used OpenTargets and DGIdb to gather evidence of 'druggability' for molecular traits with robust

327 evidence. [36-38] We found that 4/10 (40%) of the molecular traits identified in the expression analysis,

328 and none of the molecular traits identified in the gene-splicing analysis were categorised as being

329 part of the 'druggable genome'. One novel result, *HBEGF,* had three drug-gene interactions

330 (cetuximab, panitumumab and KHK-2866), the latter being an anti-HBEGF antibody which was

331 trialled for use in advanced solid tumours and ovarian cancer. However, the study was discontinued

332 after 22 months due to patients experiencing reversible neuropsychiatric toxicity, although the

333 aetiology was not understood (Supplementary Table S2). [49]

334 # Discussion

335 In this study, we used a combined MR-colocalisation framework to estimate the causal effect of
336 genetically proxied gene expression, alternative splicing and protein abundance levels on genetic
337 liability of glioma risk. We found robust evidence that causally implicated 16 molecular traits with
338 glioma risk: ten gene expression evidence levels and six alternative splicing events (one gene shared
339 both expression and splicing causal effects on glioma). Assessing different 'omics' data sources can
340 be beneficial to understand the development of complex traits and for drug target-related analyses;
341 each QTL provides an insight into different molecular processes. [16,17]

342 For 11 of the genes that we found robust evidence for here, the loci have been previously implicated
343 in GWAS/TWAS of glioma risk. [9,10] However, these studies did not establish causality of all these
344 genes, as we have. Additionally, we found four genes that not been implicated in previous genetic
345 studies: *CEP192* (18p11.21), *FAIM* (3q22.3), *HBEGF* (5q13.3) and *SLC8A1* (2p22.1). For brevity, we
346 discuss *RTEL1* and a novel result, *HBEGF*.

347 *RTEL1* (Regulator of telomere elongation helicase 1) is a gene which encodes for a DNA helicase
348 responsible for the elongation of telomeres, and is known to interact with the telosome complex, a
349 group of proteins which protect the telomere caps of DNA. [50] *RTEL1* has previously been identified as
350 a risk factor for glioma, and studies have tried to identify whether telomere length has an
351 established causative effect on the risk of glioma, although no definitive conclusion has been
352 reached.[12,14, 45-47] *RTEL1*-associated sQTLs were associated with an exon-skipping event (GTEx intron
353 ID: 63689132:63689750:clu_27064) present only in *RTEL1* transcript ENST00000425905 (P = 4.23 x
354 $10^{-75}$ to 6.64 x $10^{-18}$). Therefore, it may be the case that previous conflicting evidence on the
355 directionality of the effect of *RTEL1* expression on glioma risk may be confounded due to non-
356 canonical transcript variants; though, further studies would be required to ascertain if this is the
357 case. Furthermore, we observed that *RTEL1* sQTLs rs6063202 and rs2297440, were found to be
358 strongly associated to glioblastoma (P = 1.00 x $10^{-13}$ and 4.00 x $10^{-46}$, respectively) and with allergy-

359 related traits (P = 4.78 x $10^{-8}$ to 7.84 x $10^{-19}$, Supplementary Table S2). These results beget further
360 study and could help to understand the links between allergies, glioma risk and *RTEL1*.

361 *HBEGF* (Heparin-binding epidermal growth factor) is a member of the EGF family of growth factors
362 which is involved in the MAPK, STAT and PI3K/AKT pathways. [44,51] These molecular pathways have
363 roles in regulating biological processes, such as positive regulation of cell growth, migration, and
364 proliferation. [52] The role of *HBEGF* in the CNS is well characterised: it is highly expressed throughout;
365 has roles in both the developing and adult brain, with studies indicating *HBEGF* contributes to glial
366 and stem cell proliferation and is a ligand for EGFR.[53,54] Furthermore, expression of *HBEGF* has been
367 shown to be increased significantly in many human cancer types, and *HBEGF* mRNA expression has
368 been shown to be increased two- to five-fold in glioblastoma cell lines compared to control brain
369 tissue. [55] We found no significant differences between control and any glioma subtypes but did find
370 differential expression between GB and non-GB subtypes in two independent datasets
371 (Supplementary Figure S4A&B). [48,56] We also found that the instrumented *HBEGF* eQTL (rs4150197)
372 had no associations with cancer risk or any putative risk factors for glioma (Supplementary Table S2).
373 Unlike *RTEL1*, we observed no evidence for an effect through non-canonical transcripts or proteins.
374 Altogether, our causal evidence implicates the expression of *HBEGF* in the brain as a potentially
375 novel biomarker, though more research would be required to ascertain its role. Given that there are
376 drugs which target *HBEGF*, glioma and *HBEGF* may make for an interesting target-indication pair for
377 future studies.

## 378 Strengths

379 We aimed to identify molecular traits with the most robust evidence for causal roles in glioma risk,
380 by combining strong MR evidence with colocalisation and Steiger filtering. To test if the causal
381 effects were driven via putative glioma risk factors, we tested for potential pleiotropic effects in
382 known risk factors for glioma: allergies, asthma, altered low-density lipoprotein cholesterol (LDLc)
383 levels and alcohol consumption. This may provide evidence of horizontal pleiotropy, which may

make it harder to draw decisive conclusions of causality [27,29] However, this would require follow up studies to investigate which could lead to potentially elucidating how these putative risk factors and molecular traits are linked to glioma.

## Limitations

Despite using relatively large datasets, our analyses are still likely to suffer from limited statistical power due to restricted sample sizes, particularly in the sQTL dataset (n = 114 to 209). This might lead to some important causal effects not being identified. All three QTL datasets were derived from a mixture of case and control samples. However, the cases were derived from individuals whose disease (e.g. Alzheimer's disease in BrainQTL) have no known link to glioma risk.

Additionally, as we used the GTEx sGenes, only the top splice event per gene was measured, and therefore there were many splice events which were not tested in our MR analysis.

Most of the MR analyses used a single SNP instrument, which restricts the type of sensitivity analyses that could be performed; however, this is a common phenomenon observed when conducting MR with molecular traits. [29]

SNPs can act via multiple molecular QTL pathways and are not mutually exclusive; SNPs affecting gene expression can also be associated with alternative gene splicing of the same genes. As eQTL and sQTL are both measured by quantifying mRNA levels, this was not unexpected. [57] These SNPs may be legitimately affecting both gene expression and alternative splicing, however if a particular splice variant alters the ability of a gene to be efficiently measured, it appears that gene expression is altered, and the effect is driven by the splicing event. [58] Furthermore, some probes for mRNA will detect commonly splice variants as canonical transcripts, which are included in 'bulk tissue' eQTL analysis. This can lead to the false assumption that both expression and splicing events are driving the causal effect, when this is not the case. [59]

407 Our analysis is limited to individuals with European ancestry; therefore, it will be important to
408 extend these analyses to individuals of alternative ancestries as such data becomes available. [60]
409 Previous GWAS and observational studies in non-European cohorts have found novel associations
410 which we did not find in our study e.g., *GSTP1*, which may illustrate that the loci appear to be
411 population specific, or may be observational, and not causal. [61,62]

412 The nature of glioma can result in variation in inter-patient, intra-tumoural, subtype and
413 spatiotemporal heterogeneity, which can lead to variation in tissue recovery at biopsy. [63,64] These
414 factors can result in deviation in the profile of disease, which can make our results more
415 generalisable and less specific to one subtype of glioma. To make our analysis more precise, we
416 would require more granular tissue and cell-specific data.

# Conclusion

We conducted a robust multi-omic causal analysis for gene and protein molecular traits in brain tissue on glioma risk. We used tissue-specific molecular data and glioma subtype information to explore the nature of the causal relationships identified. Here, we combined MR with colocalisation and Steiger filtering to ensure the robustness of our results.

We provide robust multi-omic causal evidence for 11 previously implicated genes which affect the risk of glioma. We also present novel evidence for a causal effect of increased *HBEGF* expression in cortex on increased risk of all glioma, and present novel evidence for causal effects of *CEP192*, *FAIM* and *SLC8A1* splicing in multiple tissues on variable risk of all glioma and GB. Additionally, we show evidence for the causal effect of increased *HEATR3* expression and alternative splicing on increased risk of all glioma, although we propose that this effect is eQTL-specific.

We did not identify any causal proteins for glioma risk, likely due to the limited sample size of the currently available brain pQTL data.

We focussed on the causal effects of increased *HBEGF* expression and alternative splicing of *RTEL1* and use multiple investigate methods to provide evidence to understand the biological mechanisms that these genes may play in the risk of glioma.

# Abbreviation List

**CNS** – Central nervous system

**DGIdb** – Drug gene interaction database

**eQTL** – Expression quantitative trait loci

**GB** – Glioblastoma

**GWAS** – Genome-wide association study

**LD** – Linkage disequilibrium

**LDLc** – Low-density lipoprotein cholesterol

**MR** – Mendelian randomisation

**OR** – Odds ratio

**pQTL** – Protein quantitative trait loci

**QTL** – Quantitative trait loci

**sQTL** – Splicing quantitative trait loci

**TPM** – Transcripts per Million

**WHO** – World Health Organisation

# Declarations

## Ethics approval and consent to participate

This study uses previously published summary-level data and thus contains no patient identifiable data. Ethical approval and informed consent from each participant were given and can be found where the dataset was initially described. All procedures performed in studies involving human participants were done in accordance with the ethical standards of the institutional or national research committee and with 1964 Helsinki declaration.

## Consent for publication

Not applicable

## Availability of data and materials

The MetaBrain meta-analyses eQTL data can be accessed at https://www.metabrain.nl/. The GTEx sQTL v8 data can be accessed at https://gtexportal.org/home/datasets. The BrainQTL pQTL data can be found at https://www.synapse.org/#!Synapse:syn24172458.The glioma data may be accessed under the European Genome-phenome Archive accession number EGAD00010001657 (https://www.ebi.ac.uk/ega/datasets/EGAD00010001657).

## Competing interests

The authors declare they have no competing interests.

## Funding

ZAT, LJA, LP and JWR receive support from the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/4, MC_UU_00011/1). ZAT receives funding from Southmead Hospital Charitable Funds: Brain tumour bank and research fund 8036. LJA and KMK are funded by Cancer Research UK (grant number C30758/A29791). JWR received funding from Biogen for unrelated projects. KMK is funded by Innovate (grant number 10027624). This study was supported by the National Institute for Health and Care Research Bristol Biomedical Research

Centre (NIHR203315) and Cancer Research UK (grant number C18281/A29019 and C18281/A30905). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## Authors' contributions

ZAT wrote the manuscript, performed all statistical analysis and interpreted results; LJA and HZ revised the manuscript; JZ advised on statistical methodology; LP substantially revised the manuscript and assisted with statistical analysis; JWR substantially revised the manuscript, assisted with statistical analysis and interpreted results and designed the study; KMK designed the study. All authors have approved the submitted version of the manuscript.

## Acknowledgements

We would like to acknowledge all patients who provided data that made this work possible.

# References


1. Goodenberger, M.L., and Jenkins, R.B. (2012). Genetics of adult glioma. Cancer Genet. *205*, 613-621. 10.1016/j.cancergen.2012.10.009.
2. Ostrom, Q.T., Bauchet, L., Davis, F.G., Deltour, I., Fisher, J.L., Langer, C.E., Pekmezci, M., Schwartzbaum, J.A., Turner, M.C., Walsh, K.M., et al. (2014). The epidemiology of glioma in adults: a "state of the science" review. Neuro-Oncology *16*, 896-913. 10.1093/neuonc/nou087.
3. Rouse, C., Gittleman, H., Ostrom, Q.T., Kruchko, C., and Barnholtz-Sloan, J.S. (2016). Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-Oncology *18*, 70-77. 10.1093/neuonc/nov249.
4. Ostrom, Q.T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., and Barnholtz-Sloan, J.S. (2017). CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology *19*, V1-V88. 10.1093/neuonc/nox158.
5. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., and Ellison, D.W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. *131*, 803-820. 10.1007/s00401-016-1545-1.
6. Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C., Ng, H.K., Pfister, S.M., Reifenberger, G., et al. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology *23*, 1231-1251. 10.1093/neuonc/noab106.
7. Butler, M., Pongor, L., Su, Y.T., Xi, L.Q., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., and Wu, J. (2020). *MGMT* Status as a Clinical Biomarker in Glioblastoma. Trends Cancer *6*, 380-391. 10.1016/j.trecan.2020.02.010.

509 8. Hau, P., Stupp, R., and Hegi, M.E. (2007). MGMT methylation status: The advent of stratified
510 therapy in glioblastoma? Dis. Markers *23*, 97-104. 10.1155/2007/159242.
511 9. Melin, B.S., Barnholtz-Sloan, J.S., Wrensch, M.R., Johansen, C., Il'yasova, D., Kinnersley, B.,
512 Ostrom, Q.T., Labreche, K., Chen, Y.W., Armstrong, G., et al. (2017). Genome-wide
513 association study of glioma subtypes identifies specific differences in genetic susceptibility to
514 glioblastoma and non-glioblastoma tumors. Nature Genetics *49*, 789-+. 10.1038/ng.3823.
515 10. Atkins, I., Kinnersley, B., Ostrom, Q.T., Labreche, K., Il'yasova, D., Armstrong, G.N., Eckel-
516 Passow, J.E., Schoemaker, M.J., Nothen, M.M., Barnholtz-Sloan, J.S., et al. (2019).
517 Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for
518 Glioma. Cancer Research *79*, 2065-2071. 10.1158/0008-5472.can-18-2888.
519 11. Schwartzbaum, J.A., Fisher, J.L., Aldape, K.D., and Wrensch, M. (2006). Epidemiology and
520 molecular pathology of glioma. Nat. Clin. Pract. Neurol. *2*, 494-503. 10.1038/ncpneuro0289.
521 12. Saunders, C.N., Kinnersley, B., Culliford, R., Cornish, A.J., Law, P.J., and Houlston, R.S. (2022).
522 Relationship between genetically determined telomere length and glioma risk. Neuro-
523 Oncology *24*, 171-181. 10.1093/neuonc/noab208.
524 13. Kinnersley, B., Houlston, R.S., and Bondy, M.L. (2018). Genome-Wide Association Studies in
525 Glioma. Cancer Epidemiol. Biomarkers Prev. *27*, 418-428. 10.1158/1055-9965.epi-17-1080.
526 14. Haycock, P.C., Burgess, S., Nounu, A., Zheng, J., Okoli, G.N., Bowden, J., Wade, K.H., Timpson,
527 N.J., Evans, D.M., Willeit, P., et al. (2017). Association Between Telomere Length and Risk of
528 Cancer and Non-Neoplastic Diseases A Mendelian Randomization Study. JAMA Oncol. *3*, 636-
529 651. 10.1001/jamaoncol.2016.5945.
530 15. Albert, F.W., and Kruglyak, L. (2015). The role of regulatory variation in complex traits and
531 disease. Nat. Rev. Genet. *16*, 197-212. 10.1038/nrg3891.
532 16. Walker, R.L., Ramaswami, G., Hartl, C., Mancuso, N., Gandal, M.J., De La Torre-Ubieta, L.,
533 Pasaniuc, B., Stein, J.L., and Geschwind, D.H. (2019). Genetic Control of Expression and

534 Splicing in Developing Human Brain Informs Disease Mechanisms. Cell *179*, 750-+.
535 10.1016/j.cell.2019.09.021.
536 17. Eales, J.M., Jiang, X., Xu, X.G., Saluja, S., Akbarov, A., Cano-Gamez, E., McNulty, M.T., Finan,
537 C., Guo, H., Wystrychowski, W., et al. (2021). Uncovering genetic mechanisms of
538 hypertension through multi-omic analysis of the kidney. Nature Genetics *53*, 630-+.
539 10.1038/s41588-021-00835-w.
540 18. Sun, Y.V., and Hu, Y.J. (2016). Integrative Analysis of Multi-omics Data for Discovery and
541 Functional Studies of Complex Human Diseases. In Advances in Genetics, Vol 93, T.
542 Friedmann, J.C. Dunlap, and S.F. Goodwin, eds. (Elsevier Academic Press Inc), pp. 147-190.
543 10.1016/bs.adgen.2015.11.004.
544 19. Smith, G.D., and Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology
545 contribute to understanding environmental determinants of disease? Int. J. Epidemiol. *32*, 1-
546 22. 10.1093/ije/dyg070.
547 20. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and
548 Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association
549 Studies Using Summary Statistics. PLoS Genet. *10*, 15, e1004383.
550 10.1371/journal.pgen.1004383.
551 21. de Klein, N., Tsai, E.A., Vochteloo, M., Baird, D., Huang, Y.F., Chen, C.Y., van Dam, S., Oelen,
552 R., Deelen, P., Bakker, O.B., et al. (2023). Brain expression quantitative trait locus and
553 network analyses reveal downstream effects and putative drivers for brain-related diseases.
554 Nature Genetics, 24. 10.1038/s41588-023-01300-6.
555 22. Aguet, F., Barbeira, A.N., Bonazzola, R., Brown, A., Castel, S.E., Jo, B., Kasela, S., Kim-
556 Hellmuth, S., Liang, Y.Y., Parsana, P., et al. (2020). The GTEx Consortium atlas of genetic
557 regulatory effects across human tissues. Science *369*, 1318-1330. 10.1126/science.aaz1776.
558 23. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., and Wilson, R.S. (2012). Overview and Findings
559 from the Religious Orders Study. Curr. Alzheimer Res. *9*, 628-645.

560 24. Bennett, D.A., Schneider, J.A., Buchman, A.S., Barnes, L.L., Boyle, P.A., and Wilson, R.S.
561 (2012). Overview and Findings from the Rush Memory and Aging Project. Curr. Alzheimer
562 Res. *9*, 646-663.
563 25. Robins, C., Liu, Y., Fan, W., Duong, D.M., Meigs, J., Harerimana, N.V., Gerasimov, E.S.,
564 Dammer, E.B., Cutler, D.J., Beach, T.G., et al. (2021). Genetic control of the human brain
565 proteome. Am. J. Hum. Genet. *108*, 400-410. 10.1016/j.ajhg.2021.01.012.
566 26. Burgess, S., Small, D.S., and Thompson, S.G. (2017). A review of instrumental variable
567 estimators for Mendelian randomization. Stat. Methods Med. Res. *26*, 2333-2355.
568 10.1177/0962280215597579.
569 27. Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N., and Smith, G.D. (2008). Mendelian
570 randomization: Using genes as instruments for making causal inferences in epidemiology.
571 Stat. Med. *27*, 1133-1163. 10.1002/sim.3034.
572 28. Staiger, D., and Stock, J.H. (1997). Instrumental variables regression with weak instruments.
573 Econometrica *65*, 557-586. 10.2307/2171753.
574 29. Hemani, G., Bowden, J., and Smith, G.D. (2018). Evaluating the potential role of pleiotropy in
575 Mendelian randomization studies. Hum. Mol. Genet. *27*, R195-R208. 10.1093/hmg/ddy163.
576 30. Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based application for exploring
577 population-specific haplotype structure and linking correlated alleles of possible functional
578 variants. Bioinformatics *31*, 3555-3557. 10.1093/bioinformatics/btv402.
579 31. Elsworth, B.L., Lyon, M.S., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer, T.,
580 Haberland, V., Smith, G.D., et al. (2020). The MRC IEU OpenGWAS data infrastructure.
581 bioRxiv. 10.1101/2020.08.10.244293.
582 32. Mitchell, R., Elsworth, B.L., Mitchell, R., Raistrick, C.A., Paternoster, L., Hemani, G., and
583 Gaunt, T. (2019). MRC IEU UK Biobank GWAS pipeline version 2.
584 33. Kamat, M.A., Blackshaw, J.A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth,
585 A.S., and Staley, J.R. (2019). PhenoScanner V2: an expanded tool for searching human

586 genotype-phenotype associations. Bioinformatics *35*, 4851-4853.
587 10.1093/bioinformatics/btz469.
588 34. Howell, A.E., Robinson, J.W., Wootton, R.E., McAleenan, A., Tsavachidis, S., Ostrom, Q.T.,
589 Bondy, M., Armstrong, G., Relton, C., Haycock, P., et al. (2020). Testing for causality between
590 systematically identified risk factors and glioma: a Mendelian randomization study. Bmc
591 Cancer *20*, 11. 10.1186/s12885-020-06967-2.
592 35. Bowman, R.L., Wang, Q.H., Carro, A., Verhaak, R.G.W., and Squatrito, M. (2017). GlioVis data
593 portal for visualization and analysis of brain tumor expression datasets. Neuro-Oncology *19*,
594 139-141. 10.1093/neuonc/now247.
595 36. Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C.,
596 Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., et al. (2021). Open Targets Platform:
597 supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. *49*,
598 D1302-D1310. 10.1093/nar/gkaa1027.
599 37. Orchard, S., Ammari, M., Aranda, B., Breuza, L., Briganti, L., Broackes-Carter, F., Campbell,
600 N.H., Chavali, G., Chen, C., del-Toro, N., et al. (2014). The MIntAct project-IntAct as a
601 common curation platform for 11 molecular interaction databases. Nucleic Acids Res. *42*,
602 D358-D363. 10.1093/nar/gkt1115.
603 38. Freshour, S.L., Kiwala, S., Cotto, K.C., Coffman, A.C., McMichael, J.F., Song, J.J., Griffith, M.,
604 Griffith, O.L., and Wagner, A.H. (2021). Integration of the Drug-Gene Interaction Database
605 (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. *49*, D1144-D1151.
606 10.1093/nar/gkaa1084.
607 39. Hemani, G., Zhengn, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess,
608 S., Bowden, J., Langdon, R., et al. (2018). The MR-Base platform supports systematic causal
609 inference across the human phenome. eLife *7*, 29, e34408. 10.7554/eLife.34408.
610 40. RCoreTeam (2021). R: A Language and Environment for Statistical Computing.
611 https://www.R-project.org/.

612 41. RStudioTeam (2020). RStudio: Integrated Development for R. http://www.rstudio.com/.
613 42. Robinson, J.W., Hemani, G., Babaei, M.S., Huang, Y., Baird, D.A., Tsai, E.A., Chen, C.-Y.,
614 Gaunt, T.R., and Zheng, J. (2022). An efficient and robust tool for colocalisation: Pair-wise
615 Conditional and Colocalisation (PWCoCo). BioRxiv.
616 https://doi.org/10.1101/2022.08.08.503158
617 43. Yang, J., Ferreira, T., Morris, A.P., Medland, S.E., Madden, P.A.F., Heath, A.C., Martin, N.G.,
618 Montgomery, G.W., Weedon, M.N., Loos, R.J., et al. (2012). Conditional and joint multiple-
619 SNP analysis of GWAS summary statistics identifies additional variants influencing complex
620 traits. Nature Genetics *44*, 369-U170. 10.1038/ng.2213.
621 44. Medicine, N.C.f.B.I.N.L.o. HBEGF. https://www.ncbi.nlm.nih.gov/gene/1839.
622 45. Walsh, K.M., Codd, V., Smirnov, I.V., Rice, T., Decker, P.A., Hansen, H.M., Kollmeyer, T.,
623 Kosel, M.L., Molinaro, A.M., McCoy, L.S., et al. (2014). Variants near TERT and TERC
624 influencing telomere length are associated with high-grade glioma risk. Nature Genetics *46*,
625 731-735. 10.1038/ng.3004.
626 46. Walsh, K.M., Wiencke, J.K., Lachance, D.H., Wiemels, J.L., Molinaro, A.M., Eckel-Passow, J.E.,
627 Jenkins, R.B., and Wrensch, M.R. (2015). Telomere maintenance and the etiology of adult
628 glioma. Neuro-Oncology *17*, 1445-1452. 10.1093/neuonc/nov082.
629 47. Chen, Y.B., Wu, Y.S., Huang, X.J., Qu, P., Li, G., Jin, T.B., Xing, J.L., and He, S.M. (2015).
630 Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients. J.
631 Cancer Res. Clin. Oncol. *141*, 1739-1747. 10.1007/s00432-015-1938-x.
632 48. Gusev, Y., Bhuvaneshwar, K., Song, L., Zenklusen, J.C., Fine, H., and Madhavan, S. (2018). The
633 REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci. Data
634 *5*, 9, 180158. 10.1038/sdata.2018.158.
635 49. Sarantopoulos, J., Mita, M.M., Birrer, M.J., Cranmer, L.D., Campos, L.T., Zhang, X.P., Bristow,
636 P., Kaito, H., Strout, V., and Camacho, L.H. (2016). Phase 1 Study of Monotherapy with
637 KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal

638 Antibody, in Patients with Advanced Cancer. Target. Oncol. *11*, 317-327. 10.1007/s11523-
639 015-0394-5.
640 50. Medicine, N.C.f.B.I.N.L.o. RTEL1. https://www.ncbi.nlm.nih.gov/gene/51750.
641 51. Jin, K.L., Mao, X.O., Guerra, G.D., Jin, L., and Greenberg, D.A. (2005). Heparin-binding
642 epidermal growth factor-like growth factor stimulates cell proliferation in cerebral cortical
643 cultures through phosphatidylinositol 3'-kinase and mitogen-activated protein kinase. J.
644 Neurosci. Res. *81*, 497-505. 10.1002/jnr.20510.
645 52. Hatanpaa, K.J., Burma, S., Zhao, D.W., and Habib, A.A. (2010). Epidermal Growth Factor
646 Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance.
647 Neoplasia *12*, 675-684. 10.1593/neo.10688.
648 53. Wan, J., Ramachandran, R., and Goldman, D. (2012). HB-EGF Is Necessary and Sufficient for
649 Muller Glia Dedifferentiation and Retina Regeneration. Dev. Cell *22*, 334-347.
650 10.1016/j.devcel.2011.11.020.
651 54. Lemmon, M.A., and Schlessinger, J. (2010). Cell Signaling by Receptor Tyrosine Kinases. Cell
652 *141*, 1117-1134. 10.1016/j.cell.2010.06.011.
653 55. Mishima, K., Higashiyama, S., Asai, A., Yamaoka, K., Nagashima, Y., Taniguchi, N., Kitanaka,
654 C., Kirino, T., and Kuchino, Y. (1998). Heparin-binding epidermal growth factor-like growth
655 factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas.
656 Acta Neuropathol. *96*, 322-328. 10.1007/s004010050901.
657 56. Network, T.C.G.A.T.R. The Cancer Genome Atlas (TCGA) Research Network.
658 https://www.cancer.gov/tcga.
659 57. Yamaguchi, K., Ishigaki, K., Suzuki, A., Tsuchida, Y., Tsuchiya, H., Sumitomo, S., Nagafuchi, Y.,
660 Miya, F., Tsunoda, T., Shoda, H., et al. (2022). Splicing QTL analysis focusing on coding
661 sequences reveals mechanisms for disease susceptibility loci. Nat. Commun. *13*, 13, 4659.
662 10.1038/s41467-022-32358-1.

663 58. Mucaki, E.J., Shirley, B., and Rogan, P.K. (2020). Expression Changes Confirm Genomic
664 Variants Predicted to Result in Allele-Specific, Alternative mRNA Splicing. Front. Genet. *11*,
665 16, 109. 10.3389/fgene.2020.00109.
666 59. Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A.,
667 Szczesniak, M.W., Gaffney, D.J., Elo, L.L., Zhang, X.G., and Mortazavi, A. (2016). A survey of
668 best practices for RNA-seq data analysis. Genome Biol. *17*, 19, 13. 10.1186/s13059-016-
669 0881-8.
670 60. Medina-Gomez, C., Felix, J.F., Estrada, K., Peters, M.J., Herrera, L., Kruithof, C.J., Duijts, L.,
671 Hofman, A., van Duijn, C.M., Uitterlinden, A.G., et al. (2015). Challenges in conducting
672 genome-wide association studies in highly admixed multi-ethnic populations: the Generation
673 R Study. Eur. J. Epidemiol. *30*, 317-330. 10.1007/s10654-015-9998-4.
674 61. Li, G., Jin, T.B., Wei, X.B., He, S.M., Liang, H.J., Yang, H.X., Cui, Y., Chen, C., Cai, L.B., and Gao,
675 G.D. (2012). Selected polymorphisms of GSTP1 and TERT were associated with glioma risk in
676 Han Chinese. Cancer Epidemiol. *36*, 525-527. 10.1016/j.canep.2012.06.008.
677 62. Li, N., Shi, H.Y., Hou, P.F., Gao, L., Shi, Y.Q., Mi, W.Y., Zhang, G., Wang, N., Dai, W., Wei, L., et
678 al. (2021). Genetic variants of CYP4F12 gene are associated with glioma susceptibility. Int. J.
679 Cancer *149*, 1910-1915. 10.1002/ijc.33755.
680 63. Comba, A., Faisal, S.M., Varela, M.L., Hollon, T., Al-Holou, W.N., Umemura, Y., Nunez, F.J.,
681 Motsch, S., Castro, M.G., and Lowenstein, P.R. (2021). Uncovering Spatiotemporal
682 Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications.
683 Frontiers in Oncology *11*, 16, 703764. 10.3389/fonc.2021.703764.
684 64. Eisenbarth, D., and Wang, Y.A. (2023). Glioblastoma heterogeneity at single cell resolution.
685 Oncogene *42*, 2155-2165. 10.1038/s41388-023-02738-y.

686

# Figures




*Figure 1. Flowchart showing the pipeline used in the multi-omic analysis.*




*Figure 2. Directed Acyclic Graph (DAG) showing a visual representation of potential causal relationships. This DAG also shows the three assumptions of Mendelian randomisation. (1) The genetic variant(s) being used as an instrument is associated robustly with the exposure. (2) The instrument is independent of measured and unmeasured confounding factors of the association between exposure and outcome. (3) There must be no independent pathway between the instrument and outcome other than through the exposure.*




*Figure 3. Forest plot showing Mendelian randomisation results by subtype (all glioma, GB and non-GB) for the ten genes of interest in five brain tissues in the gene expression analysis. Results have strong evidence of colocalization ($H_4$ >= 80%) and correct Steiger directionality.*




*Figure 4. Forest plot showing Mendelian randomisation results by subtype (all glioma, GB and non-GB) for the six genes of interest in 12 brain tissues in the gene-splicing analysis. Results have strong evidence of colocalization ($H_4$ >= 80%) and correct Steiger directionality.*




*Figure 5. Forest plot showing Mendelian randomisation results by subtype (all glioma, GB and non-GB) for HBEGF in cortex tissue in the gene expression analysis. All subtypes show an increased risk of developing glioma, but only all glioma surpassed our Bonferroni-corrected P value threshold ($P = 5.00 \times 10^{-6}$).*

705




706

707 *Figure 6. Forest plot showing Mendelian randomisation results by subtype (all, GB and non-GB) for CEP192, FAIM and SLC8A1 in six tissues in the gene-*
708 *splicing analysis. All subtypes showed the same direction of effect on glioma risk within tissues, but not all passed our Bonferroni-corrected P value threshold*
709 *($P = 1.11 \times 10^{-5}$)*

# Tables

Table 1. Results of the MR analysis investigating the effects of genetically proxied gene expression levels on genetic liability to glioma subtype.

| Tissue | Gene | Subtype | Method | No. of SNPs | P Value | Odds Ratio (95% CI) | H4 (%) | Steiger Direction | Steiger P Value | Steiger Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| Cortex | *CDKN2B* | All | Wald ratio | 1 | 7.17E-43 | 1.36 (1.19 - 1.55) | 93 | TRUE | 2.32E-19 | TRUE |
| Cortex | *CDKN2B* | GB | Wald ratio | 1 | 6.22E-44 | 1.14 (1.08 - 1.21) | 97 | TRUE | 3.19E-15 | TRUE |
| Cortex | *CDKN2B* | Non-GB | Wald ratio | 1 | 1.59E-14 | 1.22 (1.15 - 1.29) | 92 | TRUE | 2.91E-21 | TRUE |
| Cerebellum | *EGFR* | All | Wald ratio | 1 | 1.07E-25 | 1.22 (1.14 - 1.32) | 96 | TRUE | 2.16E-10 | TRUE |
| Cerebellum | *EGFR* | GB | Wald ratio | 1 | 2.89E-31 | 0.67 (0.63 - 0.73) | 97 | TRUE | 4.29E-09 | TRUE |
| Cerebellum | *EGFR* | Non-GB | Wald ratio | 1 | 1.60E-07 | 0.58 (0.53 - 0.64) | 98 | TRUE | 2.65E-11 | TRUE |
| Basal Ganglia | *GALNT6* | All | Wald ratio | 1 | 3.14E-06 | 0.5 (0.46 - 0.55) | 100 | TRUE | 4.78E-09 | TRUE |
| Basal Ganglia | *GALNT6* | GB | Wald ratio | 1 | 9.08E-08 | 0.43 (0.38 - 0.48) | 100 | TRUE | 1.23E-08 | TRUE |
| Cerebellum | *GALNT6* | All | Wald ratio | 1 | 3.14E-06 | 1.2 (1.12 - 1.28) | 100 | TRUE | 7.94E-25 | TRUE |
| Cerebellum | *GALNT6* | GB | Wald ratio | 1 | 9.08E-08 | 1.2 (1.12 - 1.29) | 100 | TRUE | 1.76E-23 | TRUE |
| Cortex | *GALNT6* | GB | Inverse variance weighted | 2 | 1.53E-07 | 1.19 (1.13 - 1.25) | 100 | TRUE | 6.87E-130 | TRUE |
| Hippocampus | *GALNT6* | All | Wald ratio | 1 | 4.17E-06 | 6.89 (5.60 - 8.47) | 99 | TRUE | 5.29E-08 | TRUE |
| Hippocampus | *GALNT6* | GB | Wald ratio | 1 | 2.15E-07 | 1.87 (1.50 - 2.34) | 100 | TRUE | 1.09E-07 | TRUE |
| Spinal Cord | *GALNT6* | GB | Wald ratio | 1 | 8.40E-07 | 2.71 (2.16 - 3.40) | 99 | TRUE | 6.88E-07 | TRUE |
| Cortex | *HBEGF* | All | Wald ratio | 1 | 4.41E-06 | 1.17 (1.12 - 1.23) | 99 | TRUE | 8.18E-17 | TRUE |
| Basal Ganglia | *HEATR3* | All | Wald ratio | 1 | 1.50E-10 | 0.77 (0.69 - 0.85) | 93 | TRUE | 7.61E-11 | TRUE |
| Basal Ganglia | *HEATR3* | GB | Wald ratio | 1 | 1.55E-11 | 0.60 (0.53 - 0.68) | 95 | TRUE | 2.58E-11 | TRUE |
| Cerebellum | *HEATR3* | All | Wald ratio | 1 | 3.93E-11 | 1.15 (1.09 - 1.23) | 96 | TRUE | 6.45E-54 | TRUE |
| Cerebellum | *HEATR3* | GB | Wald ratio | 1 | 6.74E-12 | 1.17 (1.11 - 1.24) | 97 | TRUE | 1.25E-51 | TRUE |
| Cortex | *HEATR3* | All | Wald ratio | 1 | 1.95E-10 | 1.26 (1.18 - 1.34) | 97 | TRUE | 1.15E-139 | TRUE |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cortex | *HEATR3* | GB | Wald ratio | 1 | 8.20E-11 | 1.14 (1.1 - 1.19) | 97 | TRUE | 3.76E-125 | TRUE |
| Cerebellum | *JAK1* | GB | Wald ratio | 1 | 9.28E-09 | 1.14 (1.08 - 1.20) | 89 | TRUE | 2.68E-38 | TRUE |
| Cerebellum | *MDM4* | All | Wald ratio | 1 | 9.54E-07 | 1.18 (1.11 - 1.26) | 91 | TRUE | 2.10E-08 | TRUE |
| Cortex | *PICK1* | GB | Wald ratio | 1 | 1.92E-09 | 1.19 (1.13 - 1.26) | 91 | TRUE | 2.14E-31 | TRUE |
| Hippocampus | *PICK1* | GB | Wald ratio | 1 | 3.95E-09 | 4.43 (3.74 - 5.25) | 81 | TRUE | 1.65E-06 | TRUE |
| Cortex | *RAVER2* | All | Wald ratio | 1 | 3.19E-08 | 0.80 (0.73 - 0.87) | 94 | TRUE | 8.11E-06 | TRUE |
| Cortex | *RAVER2* | GB | Wald ratio | 1 | 7.92E-10 | 0.86 (0.81 - 0.90) | 98 | TRUE | 1.42E-04 | TRUE |
| Cortex | *TERT* | All | Wald ratio | 1 | 2.32E-66 | 1.27 (1.17 - 1.37) | 100 | TRUE | 3.55E-03 | TRUE |
| Cortex | *TERT* | GB | Wald ratio | 1 | 6.92E-75 | 1.39 (1.25 - 1.55) | 100 | TRUE | 1.18E-01 | UNCERTAIN |
| Cortex | *TERT* | Non-GB | Wald ratio | 1 | 6.69E-18 | 2.35 (1.79 - 3.08) | 100 | TRUE | 3.26E-05 | TRUE |

*Results presented are those which were deemed the most robust, i.e., met the Bonferroni-correct P value threshold ($P = 5.00 \times 10^{-6}$) for the MR analysis, had strong evidence of colocalisation (H4 > 80%) and correctly orientated Steiger filtering direction.*

715 *Table 2. Results of the MR analysis investigating the effects of genetically proxied gene splicing levels on genetic liability to glioma subtype.*

| Tissue | Gene (Splice Junction) | Subtype | Method | No. of SNPs | P Value | Odds Ratio (95% CI) | H4 (%) | Steiger Direction | Steiger P Value | Steiger Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| Amygdala | *FAIM Splice Junction 5* | All | Wald ratio | 1 | 1.03E-05 | 2.72 (1.74 - 4.25) | 97 | TRUE | 6.91E-01 | UNCERTAIN |
| Amygdala | *RTEL1 Splice Junction 32* | All | Wald ratio | 1 | 4.38E-40 | 12.83 (8.80 - 18.72) | 100 | TRUE | 9.68E-01 | UNCERTAIN |
| Amygdala | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 8.36E-10 | 4.61 (2.83 - 7.51) | 98 | TRUE | 7.34E-01 | UNCERTAIN |
| Anterior Cingulate Cortex | *RTEL1 Splice Junction 32* | All | Wald ratio | 1 | 3.89E-33 | 0.09 (0.06 - 0.13) | 94 | TRUE | 9.46E-01 | UNCERTAIN |
| Anterior Cingulate Cortex | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 2.39E-08 | 0.23 (0.14 - 0.39) | 92 | TRUE | 7.24E-01 | UNCERTAIN |
| Caudate | *FAIM Splice Junction 5* | All | Wald ratio | 1 | 1.09E-05 | 3.01 (1.84 - 4.92) | 97 | TRUE | 6.83E-01 | UNCERTAIN |
| Caudate | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 1.56E-10 | 7.13 (3.91 - 13.02) | 100 | TRUE | 8.68E-01 | UNCERTAIN |
| Cerebellar Hemisphere | *CEP192 Splice Junction 60* | GB | Wald ratio | 1 | 9.78E-06 | 4.40 (2.28 - 8.48) | 97 | TRUE | 7.79E-01 | UNCERTAIN |
| Cerebellar Hemisphere | *RTEL1 Splice Junction 32* | GB | Wald ratio | 1 | 1.58E-45 | 19.1 (12.7 - 28.72) | 100 | TRUE | 7.79E-01 | UNCERTAIN |
| Cerebellar Hemisphere | *RTEL1 Splice Junction 32* | All | Wald ratio | 1 | 4.38E-40 | 9.52 (6.82 - 13.28) | 100 | TRUE | 8.87E-01 | UNCERTAIN |
| Cerebellar Hemisphere | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 8.36E-10 | 3.85 (2.51 - 5.93) | 95 | TRUE | 6.23E-01 | UNCERTAIN |
| Cerebellum | *HEATR3 Splice Junction 1* | All | Wald ratio | 1 | 1.29E-10 | 9.64 (4.83 - 19.24) | 91 | TRUE | 9.38E-01 | UNCERTAIN |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cerebellum | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 2.32E-10 | 5.21 (3.13 - 8.68) | 99 | TRUE | 7.43E-01 | UNCERTAIN |
| Cortex | *RTEL1 Splice Junction 32* | GB | Wald ratio | 1 | 4.42E-47 | 52.42 (30.59 - 89.81) | 100 | TRUE | 6.97E-01 | UNCERTAIN |
| Frontal Cortex | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 2.00E-10 | 5.28 (3.16 - 8.82) | 99 | TRUE | 7.94E-01 | UNCERTAIN |
| Hippocampus | *FAIM Splice Junction 5* | All | Wald ratio | 1 | 1.09E-05 | 2.76 (1.76 - 4.34) | 97 | TRUE | 6.64E-01 | UNCERTAIN |
| Hippocampus | *PHLDB1 Splice Junction 5* | All | Wald ratio | 1 | 7.83E-09 | 0.11 (0.05 - 0.24) | 87 | TRUE | 9.29E-01 | UNCERTAIN |
| Hippocampus | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 8.36E-10 | 5.05 (3.01 - 8.46) | 96 | TRUE | 8.08E-01 | UNCERTAIN |
| Hypothalamus | *PHLDB1 Splice Junction 3* | All | Wald ratio | 1 | 8.40E-15 | 13.29 (6.92 - 25.55) | 99 | TRUE | 9.94E-01 | UNCERTAIN |
| Hypothalamus | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 2.00E-10 | 6.02 (3.46 - 10.47) | 99 | TRUE | 8.12E-01 | UNCERTAIN |
| Nucleus Accumbens | *FAIM Splice Junction 5* | All | Wald ratio | 1 | 1.03E-05 | 3.43 (1.98 - 5.93) | 97 | TRUE | 7.29E-01 | UNCERTAIN |
| Nucleus Accumbens | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 2.32E-10 | 5.92 (3.41 - 10.25) | 99 | TRUE | 8.16E-01 | UNCERTAIN |
| Putamen | *RTEL1 Splice Junction 32* | Non-GB | Wald ratio | 1 | 1.56E-10 | 5.35 (3.2 - 8.93) | 100 | TRUE | 7.66E-01 | UNCERTAIN |
| Substantia Nigra | *SLC8A1 Splice Junction 7* | All | Wald ratio | 1 | 5.72E-06 | 0.37 (0.24 - 0.56) | 98 | TRUE | 7.01E-01 | UNCERTAIN |

*Results presented here are those which were deemed the most robust, i.e., met the Bonferroni-correct P value threshold ($1.11 \times 10^{-5}$) for the MR analysis, had strong evidence of colocalisation (H4 > 80%) and correctly orientated Steiger filtering direction.*